NEXI — NexImmune, Inc.
$0.00
+$0.00 (+0.00%)
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a vivo directly injectable modality platform.
Market Cap
$139.00
Forward P/E
-0.0x
52-Week Range
N/A
NEXI Price History
Revenue vs. Net Income
$0
Revenue · FY2022
Annual. Net margin is shown under each year.
Free Cash Flow
-$52.4M
FCF · FY2022
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-192.8%
ROCE · FY2022
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
4.0x
Assets ÷ liabilities · FY2022
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+19.2%
Dilution · FY2022
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
